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Mitoxantrone Represses Markers of Microglial Activation and Inflammation 
Cameron A. Tull 
Abstract 
Multiple sclerosis (MS) is a neurodegenerative disease characterized by an autoimmune 
attack against myelin sheaths in the central nervous system (CNS). Resulting debilitations vary 
from sensory, motor, and coordination abnormalities to visual difficulties as well as bowel, 
bladder, sexual, and cognitive dysfunction (Fox, 2006). Mitoxantrone (Novantrone) is an FDA-
approved drug used to treat the secondary-progressive form ofMS due to its demonstrated 
immunosuppressive properties. While the mechanism of action of mitoxantrone is not yet well 
understood, and is limited in its use due to cardiotoxicity, the aim of this study was to determine 
the effect of mitoxantrone on microglial and astrocyte activation as a measure of the 
inflammatory response. Enzyme-linked immunosorbent assays (ELISA) showed that 
lipopolysaccharide (LPS) stimulates markers of activation including nitric oxide (NO), 
interleukin-1-beta (IL-l b), interleukin-6 (IL-6), and monocyte chemoattractant protein-1 (MCP-1) 
in N9 cultured microglia, and moreover, that mitoxantrone inhibits these effects in a dose-
dependent manner. 
Introduction 
MS 
The purpose of our research was to determine the specific effects of mitoxantrone on 
LPS-induced activated microglial cells to elucidate the pathways through which it alters the 
inflammatory response characteristic of secondary progressive multiple sclerosis. 
Up to 2 million people are affected by multiple sclerosis world-wide, and approximately 
300,000 to 350,000 individuals suffer from MS in the United States alone (Anderson et al., 1992). 
Although women are twice as likely as men to develop MS (Fox, 2006), the disease is often 
more severe in men (Voskuhl and Palaszynski, 2001). MS may be diagnosed in people between 
the ages oftwenty and sixty, but it is most commonly diagnosed between the ages twenty-five to 
forty years of age (Simone et al., 2000). 
Multiple sclerosis is a chronic inflammatory disease of the central nervous system and is 
characterized as an autoimmune reaction against the myelin sheaths that surround the nerves. In 
MS the primary pathological target is myelin and it is this demyelination, oligodendrocyte loss, 
and axonal degeneration that lead to the subsequent loss of neurological function (Trapp, 1999). 
Patients affected by MS typically are found to have multiple lesions in cerebral white matter, and 
these areas of inflammation have been seen both in autopsy specimens as well as with the use of 
magnetic resonance imaging (MRI) (Fox, 2006). Lesions found in the brainstem, corpus 
callosum, juxtacortical area, or adjacent to the body of the lateral ventricles, are most specific for 
MS (Fox, 2006). Often these lesions are oriented perpendicularly to the lateral ventricle and are 
round or ovoid (Fox, 2006). There is indication ofbreakdown of the blood-brain barrier resulting 
from the development ofMS lesions. This results in the invasion ofhematogenous monocytes 
and T cells into the brain parenchyma (Trapp, 1999). The immune system is implicated in active 
tissue destruction by the association of inflammatory cells with new MS lesions (Trapp, 1999). 
The most common form of multiple sclerosis usually strikes young adults and is termed 
classical MS. Classical MS is usually marked by two distinct phases: relapsing-remitting and 
secondary progressive. Initially, MS presents in relapsing-remitting form, a phase which can last 
8-20 years before succeeding onto the secondary progressive stage, which is marked by 
continuously progressive disabilities of the nervous system (Trapp, June 1999). With the 
relapsing-remitting form ofMS, periods of sporadic neurological deficits are intermittent with 
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variable periods of remission. There is no way to predict the onset of the secondary progressive 
phase, and the mechanisms by which relapsing-remitting converts into secondary progressive 
MS are not understood (Trapp, June 1999). Due to the fact that the vast majority of neurological 
disability in patients suffering from MS is accounted for in the secondary progressive phase, it is 
this phase that multiple sclerosis researchers are trying to prevent by first elucidating the 
pathological processes responsible so that effective therapies might be developed. 
Immune Response 
Humans are protected from foreign pathogens, both bacterial and viral, by the immune 
system. There are two systems of immunity - innate, or natural immunity, and acquired, also 
known as adaptive or specific immunity. Essentially, what distinguishes the two types of 
immunity is their respective way of recognizing microorganisms (Fearon and Locksley, 1996). 
Innate immunity utilizes encoded proteins to recognize potentially harmful substances. For 
example, macrophages have a receptor for lipopolysaccharide (LPS), a component of Gram-
negative bacterial cell membranes, which signals the presence of infection by eliciting cytokine 
synthesis. Some such cytokines are interleukin-1 (IL-l), IL-6, IL-12, and tumor necrosis factor 
(TNF). The function of these cytokinesis to elicit immune response mechanisms such as 
development of helper T cells and stimulation of macrophage activity (Fearon and Locksley, 
1996). The innate immune response is mediated by various cells types such as neutrophils, 
macrophages, and dendritic cells (Janeway et al., 1999a). Essentially the innate response is able 
to react immediately and destroy pathogens upon detection, whereas the acquired immune 
response requires time to plan a course of attack. Apparently, there are innate receptors present 
on all cells that are specific for certain types of pathogens, and these receptors allow for the 
immediacy ofthe innate immune response (Janeway, 1992). 
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Acquired immunity, on the other hand, comprises lymphocytes and is very adaptable 
(Fearon and Locksley, 1996). Adaptive (acquired) immunity is mediated by T -lymphocytes (T 
cells) and B-lymphocytes (B cells), each of which produces T cell receptors and B cell receptors 
respectively, which recognize foreign and self-antigens. These receptors are known to be part of 
the immunoglobulin family of proteins. As a result of extensive recombination of the genes that 
code for these receptors, each cell exhibits a structurally unique receptor. This recombination of 
genes takes place during early development and also results in production ofT cells and B cells 
that express specific receptors capable of recognizing a wide range ofboth foreign and self-
antigens (Medzhitov and Janeway, 2000). In 1959 Burnet mapped out the theory of clonal 
selectivity, which still serves to explain the notion of autoimmunity - how individuals are 
protected from self-tissue attack by the immune system. According to this theory, at the time of 
T cell differentiation in the thymus, autoreactive T cells are deleted. This process results in a 
wide range ofT cells and B cells that recognize foreign but not self-antigens in the mature 
individual (Burnet, 1970). Furthermore, aT cell orB cell specific for an antigen that becomes 
activated by that antigen will undergo proliferation in order to produce sufficient numbers of 
cells necessary for an adequate response. This process is referred to as clonal expansion and 
results in the output of effector cells that respond directly against the pathogen that stimulated 
both their production and the production of memory cells. Memory cells allow for a more rapid 
response in the event of subsequent exposure. Memory cells are lymphocytes, and their 
production serves as the foundation for both active and passive immunity. Active immunity 
occurs in response to infection of pathogens whereas passive immunity occurs in response to 
antigens from inactivated pathogens following vaccination (Picker and Siegelman, 1999). 
Although it is clear that acquired immunity provides the body with powerful long-term immunity 
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and is highly antigen specific, acquired immunity is ineffective until memory and effector 
lymphocytes are produced. This process can take up to two weeks, making innate immunity vital 
in that it holds the invading pathogen in check, thus giving the acquired immune response time to 
gather forces for attack (Janeway et al., 1999b, c). 
Etiology of MS 
MS is considered an autoimmune disease because, in individuals suffering from MS, the 
immune system attacks self-antigens in the body's CNS. It is this self-attack that causes 
neuropathology. In an effort to explain the development of autoinununity, there are two primary 
theories that will be discussed here: the molecular mimicry theory and the clonal selection theory 
(Rouse and Deshpande, 2002; Burnet, 1959). Molecular mimicry is the idea that an immune 
response can be elicited by viral antigens that maintain sufficient molecular similarity to self-
antigens. The reason that autoimmune diseases do not develop under normal circumstances is 
that during development, lymphocytes that have high affinity receptors for self antigens are 
deactivated (Rouse and Deshpande, 2002). Although autoreactive lymphocytes are still present, 
they are not activated in normal healthy individuals. Also, it has been shown that lymphocyte 
receptors on T cells might not be as specific as once thought. In effect, several epitopes might 
have the capability of reacting with a single receptor due to this degeneration ofT cell 
recognition specificity. An epitope is the surface portion of an antigen. It is capable of both 
eliciting an immune response and of combining with the antibody produced to counter that 
response (Houghton Mifflin, 2002) . In essence, once an antigen has exacted a response, the 
expansion ofT cell clones could react with other epitopes not excluding self proteins presented 
by self major histocompatibility complex (MHC) (Rouse and Deshpande, 2002). Although the 
' 
specific cause ofMS is not known, many viruses could contribute its pathogenesis. This is 
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considered a possibility by some based on observations that relapses of symptoms in those 
suffering from MS are often preceded by microbial infections (Martinet al., 2001). In short, viral 
infections could initiate and cause expression of autoimmune disease when they result in a cross-
reaction between host autoreactive T cells and the foreign agents (Rouse and Deshpande, 2002). 
The invading virus activates myelin-specific T cells by molecular mimicry (Martinet al., 2001). 
As mentioned earlier, lymphocytes that have high-affinity receptors for self antigens are 
eliminated during development. This notion is the clonal selection theory of acquired immunity 
(Burnet, 1959). If, as the clonal selection theory (CST) holds, all antigen receptors that might 
recognize self-antigens must be purged, then autoimmunity is technically not possible. 
Regardless, autoimmune diseases do occur, often in the aftermath of infection. Keeping true to 
the CST, receptors are deleted that recognize self-antigens; however, an infectious agent is 
capable of disregarding the deletions and instead presenting epitopes that "mimic" host epitopes. 
So, while the CST keeps the immune system from stimulating self-recognition, "pseudo-self 
recognition" can occur. Accordingly, the clonal selection and molecular mimicry theories can 
coexist (Cohen, 2000). 
There are several contributing factors to the development ofMS and other autoimmune 
diseases (AID) such as environment, genetics, and hormones. It is thought that environmental 
factors play a role in triggering autoimmune disease even in individuals genetically predisposed 
to AID. According to Davidson and Diamond (200 1 ), the importance of environmental triggers 
has become evident through studies of populations that are genetically similar, but because they 
live in different locations, are exposed to differing environmental conditions. Specific gene 
mutations have been shown to correlate to several autoimmune diseases. An example is found in 
comparing the rate of AID in monozygotic and dizygotic twins (Davidson and Diamond, 2001). 
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Specifically with MS, monozygotic twins have much higher concordance of the disease. So too, 
the disease is much more common in biologically related family members than in adopted family 
members with no biological relation (Noseworthy, 1999). It should be noted that while there are 
some autoimmune diseases that result from single gene mutations, the majority are associated 
with multiple gene mutations (Wucherpfennig, 2001). 
Furthermore, hormonal control is thought to contribute to AID development. Multiple 
sclerosis occurs more often in females than males; in fact, this holds true for many other 
autoimmune diseases. While the mechanisms responsible for this gender difference are unclear, 
several studies have suggested that the disproportion is due to the influence of sex steroids on 
onset and exacerbations ofMS (Drew and Chavis, 2000). It has been observed that steroidal 
changes that occur during gestation affect symptoms of MS. In short, during the third trimester 
ofpregnancy there often is a general remission of symptoms while the postpartum period is 
marked by exacerbations (Confavreux et al., 1998). 
Since the 1970s, mitoxantrone has been used to treat various non-lymphocyte leukemias 
as well as both prostate and breast cancer (Neuhaus et al., 2006). However, in October of2000, 
the FDA approved the agent for treatment of severe forms ofrelapsing-remitting MS and 
secondary progressive MS (Koeller and Eble, 1988; Jain, 2000). Because MS is thought to be an 
autoimmune disease, immunosuppressants such as mitoxantrone might slow the progression of 
demyelination. Mitoxantrone is a powerful immunosuppressive drug that targets proliferating 
immune cells such as T and B lymphocytes and macrophages (Neuhaus et al., 2006). Chemically, 
mitoxantrone, 1 ,4-Dihydroxy-5,8-bis-[[2-[(2-hydroxyethyl]-amino ]-ethyl]-amino ]-anthraquinone 
dihydrochloride, C22H28N406 • 2HC1, is a synthetic anthracenedione derivative with a molecular 
mass of 517.4 Da (Neuhaus et al., 2006) (Figure 1 ). Mitoxantrone is a topoisomerase II inhibitor 
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(Koeller and Eble, 1988), and this interaction results in single- and double- strand breaks in DNA 
by ligating the DNA at specific sites in the course of synthesis (Neuhaus et al., 2006). What 
occurs is an arrest at an important step in synthesis and is believed to be caused by mitoxantrone 
stabilizing the cleavable complex oftopoisomerase II (Osheroff et al., 1994). This halt in cell 
cycle progression leads to an accumulation of cells in the G2 phase, and this activity of 
mitoxantrone has been demonstrated in human fibroblast cell lines (Fox and Smith, 1990). 
HO 0 H-N-CH1-CH1-NH-CH.1·CH,-OH 
• 2HCI 
Figure 1. Structure of mitoxantrone. 
Pharmacokinetically, mitoxantrone is 78% bound to plasma proteins, has a plasma half 
life somewhere between 25 and 215 hours, and is eliminated by both the liver and kidneys. 
However, from the liver and kidneys collectively, less than 35% was recovered within five days 
after administration. More so, the agent has been shown to remain in cancer patients for close to 
nine months. Unfortunately, studies on the ability of mitoxantrone to penetrate the blood-brain 
barrier have shown contradiction (Neuhaus et al., 2006). Extent of treatment is cumulative dose 
of 140 mg/m2, or a time period of2 to 3 years (Neuhaus et al., 2005). These restrictions on 
mitoxantrone treatment time and dosage are due to the drug' s association with cardiotoxicity, 
specifically congestive heart failure. The mechanisms by which mitoxantrone modulates multiple 
sclerosis have not been elucidated, and it is our hope that clarification of these pathways will 
lead to safer, more effective therapies for individuals living with this disease. 
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Role of microglia in MS 
Central to the pathology ofMS is the MS lesion and subsequent demyelination. Myelin 
destruction occurs amidst an inflammatory reaction consistent ofT cells, B cells, macrophages, 
and widespread microglial/macrophage activation (Bruck, 2005). Therefore, not only do 
autoreactive T cells play a role in MS pathology, but activated microglia are also thought to take 
part. Microglia are the primary cellular component of the endogenous CNS 
immune/inflammatory defense system (Ransohoff, 1999). These cells are found near endothelial 
cells, sporadically in the parenchyma, and in the perivenular regions (Sriram and Rodriguez, 
1997). Characteristic of microglia is their fast response to inflammation, injury, infection, and 
neurodegeneration (Benveniste, 1997). In order forT cells to recognize antigens, these antigens 
must be presented and this process is carried out by antigen presenting cells (APCs). Microglial 
ce11s can function as antigen-presenting cells and produce and respond to a wide variety of 
cytokines. However, it has been established that microglia in and surrounding MS lesions 
become activated, and upon doing so, undergo a morphological change into macrophages 
(Ransohoff, 1999). They can impair blood-brain barrier (BBB) function, mediate phagocytic 
events, and damage oligodendrocytes, the cells that produce myelin in the central nervous system 
(Benveniste, 1997). The MS inflammatory reaction is linked to an up-regulation of various 
cytokines such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-a), and chemokines 
such as mouse monocyte chemotactic protein- I (MCP-1 ). Cytokines are proteins that are made 
by cells that affect the behavior of other cells. Cytokines made by lymphocytes are often referred 
to as interleukins (IL) or lyrnphokines (Janeway and Travers, 1994). Chemokines are simply 
small cytokines and are involved in migration and activation of cells, specifically phagocytic 
cells and lymphocytes (Janeway and Travers, 1994). The activated microglia produce these 
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cells and lymphocytes (Janeway and Travers, 1994). The activated microglia produce these 
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Figure 2 represents a schematic model ofCNS demyelination As seen, the process is 
initiated by microglial activating factors. Activated microglia secrete cytokines, organic 
molecules, excitatory amino acids, and chemokines that sustain inflammation and demyelination. 
(HSP =heat shock protein; EAA =excitatory amino acid.) 
.Sul't'J 
:\nti~cn!> 
I.I'S 
liSP 
~Jicroglial Acth•ation 
Fac:tors 
CytOkllteS 
II I~ 
I !\I 
lll 
l'hal!lll.:)•tn-'1:.. 
:-.:1tm· •Jl(llk 
l~~:c 1'3drc:,fs 
EA:\ 
Chrrrwl101.'~ 
~I 
l.ymph!l<')'l~ n·cn•umrnr 
Figure 2. Schematic model ofCNS demyelination 
From: Sriram: Neurology, Volume 48(2).February 1997.464-470 
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Microglia: effects on T cell phenotype 
In order to evaluate the effects of microglia on T ceU phenotype, specific mouse strains 
are induced with experimental autoimmune encephalomyelitis (EAE). EAE is a 
neurodegenerative disease specifically occurring in rodents and serves as an animal model for 
MS (Benveniste, 1997). EAE is induced in rodents by the adoptive transfer ofCD4+ T cells that 
are specific for myelin antigens (Drew, 2005). T-helper 1 (Thl) and T-helper 2 (Th2) cells are 
the two types ofCD4+ T cells. Each type produces different types of cytokines. Thl cells 
produce and release IL-l, IL-2, TNF-a, lymphotoxin (LT), and IFN-y, whereas Th2 ceUs 
produce and release IL-4, IL-10, IFN-~, and TGF- ~.which appear to be linked to disease 
remission (Benveniste, 1997). Secondly, Thl cell response is coupled with cell-mediated 
immunity and is responsible for delayed-type hypersensitivity, while Th2 cell reaction is 
associated with humoral immunity, stimulation of allergic response mechanisms, and increased 
production of antibodies (Drew, 2005). 
Microglia: antigen presentation 
Lymphocytes are the primary components of the immune response, but they rely heavily 
on phagocytic cells of the monocyte-macrophage system for presentation of antigen toT 
lymphocytes. In the case of autoimmune disease, these APCs present self-peptides to T cells 
resulting in pathology. This process is referred to as a failure of self-tolerance (Young and Heath, 
2000). It is important to note that both the innate component, as well as the acquired component 
ofthe immune system, play a role in antigen presentation. Cells derived from monocytes, such as 
macrophages and microglia, are representative of the innate component and are collectively 
referred to as "professional APC." Equally, cells of the adaptive component are CD4+ T-helper 
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cells, CD8+ T -cells, and B cells. This class is referred to as major histocompatibility complex 
(MHC) (Drew, 2005). 
Materials 
Mitoxantrone 
Mitoxantrone, 1 ,4-Dihydroxy-5,8-bis-[[2-[(2-hydroxyethyl]-amino ]-ethyl]-amino ]-
anthraquinone dihydrochloride, (C22H2sN40 6 • 2HC1) was prepared in dimethyl sulfoxide 
(DMSO) to a final stock concentration of20 mM (Drew). 
Lipopolysaccharide (LPS) 
Lipopolysaccharide (LPS) was prepared in sterile phosphate buffer saline (PBS) to a 
stock concentration of 500flg/ml. 
Methods 
Cell Culture 
The N9 microglial cell line was derived from mouse cerebrum and immortalized by 
transfection with the v-myc oncogene (Righi et al., 1989; Corradin et al., 1993). N9 cells were 
cultured at 37° C and 5.0% C02 in Eagle's minimum essential medium with Earle's salts 
(Media tech Ce11gro, Herndon, VA) containing a final concentration of 10% fetal bovine serum 
(FBS) and 1.38mM L-glutamine (Sigma, St. Louis, MO). The N9 cell line was provided as a gift 
to Lori Hensley, Ph.D. (Ouachita Baptist University, Arkadelphia, AR, USA) by Paul Drew, 
Ph.D. (University of Arkansas for Medical Sciences, Little Rock, AR, USA). 
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MTT Assay 
Cell viability was measured with an MTT (3-(4,5-dimethylthiazone-2yl)-2,5-
diphenyltetrazolium bromide) assay, which measures mitochondrial activity. MTT solution was 
prepared by diluting MTT 1:50 with culture medium. Cell culture media was removed and 
replaced with lml MTT solution and incubated at 37° C for one hour. MTT solution was 
removed and cells were lysed by adding 1 ml DMSO/well. Plates were rocked for 30 minutes and 
read on a plate reader at 570nm. 
Nitrite Assay 
For 1 OOml Gries reagent, 1 g of sulfanilamide, 0.1 g N( 1-naphthyl)ethylenediamine 
(C12Hl4N2 2HC1), 2.5rnl phosphoric acid, and 97.5ml H20 were added together. 
Cells were plated in a 6-well plate at 6.4 x I 05 cells/well and incubated for 24 hours before 
treatment with mitoxantrone. Cells were then incubated 4 hours before inducing activation ofN9 
microglial cells with LPS. Media were harvested from wells after 24 hours, and 501!1 of each 
sample was added to a 96-well plate with 501!1 Gries reagent and read on a plate reader at 550nm. 
IL-6 ELISA Assay 
IL-6 production by microglia was determined according to manufacturer' s 
recommendations (BD Biosciences-PharMingen, San Diego, CA). For analysis ofiL-6, 
microwells were coated with 100111 per well of Capture Antibody diluted in Coating Buffer. The 
plate was sealed and incubated overnight at 4° C. The wells were aspirated and washed 3 times 
with 3001!1/well ofwash buffer. The plates were then blocked with 200111/well of Assay Diluent. 
The plate was then incubated at room temperature for 1 hour. The wells were again aspirated and 
washed 3 times with 3001!1/well of wash buffer. Standard and sample dilutions in Assay Diluent 
were prepared. 100111 of each standard, sample, and control were pipetted into appropriate wells. 
14 
The plate was sealed and incubated for 2 hours at room temperature. The wells were again 
aspirated and washed, but with a total of 5 washes. I OOf.!l of Working Detector (Detection 
Antibody+ SAv-HRP reagent) were added to each well, and the plate was sealed and incubated 
for 1 hour at room temperature. The wells were then washed again, but with 7 total washes. 
I OOf.!l of Substrate Solution were then added to each well. Next, the plate was left to incubate 
unsealed in the dark for 30 minutes at room temperature. 50f.!l of Stop Solution were then added 
to each well. Finally, the absorbance was read at 450nm within 30 minutes of stopping reaction. 
IL-1 p ELISA Assay 
IL-l p production by microglia was determined according to manufacturer's 
recommendations (BD Biosciences-PharMingen, San Diego, CA). For analysis ofiL-lp, 
microwells were coated with lOOf.!l per well of Capture Antibody diluted in Coating Buffer. The 
plate was sealed and incubated overnight at 4 o C. The wells were aspirated and washed 3 times 
with 300f.!llwell ofwash buffer. The plates were then blocked with 200f.!l/well of Assay Diluent. 
The plate was then incubated at room temperature for 1 hour. The wells were again aspirated and 
washed 3 times with 300f.!Vwell of wash buffer. Standard and sample dilutions in Assay Diluent 
were prepared.l OOf.!l of each standard, sample, and control were pipetted into appropriate wells. 
The plate was sealed and incubated for 2 hours at room temperature. The wells were again 
aspirated and washed, but with a total of 5 washes. I OOf.!l of Detection Antibody diluted in Assay 
Diluent were added to each well. The plate was then sealed and incubated at room temperature 
for 1 hour. The wells were again washed, with a total of five washes. Next, I OOf.!l of Enzyme 
Reagent diluted in Assay Diluent were added to each well. The plate was sealed and incubated 
for 30 minutes at room temperature. The wells were then washed with a total of7 washes, 
followed by the addition of IOOf.!l of Substrate Solution to each well. The plate was then 
RILEY·HICKif-.4GBOTHAM LIBRAHf 
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incubated without plate sealer for 30 minutes at room temperature in the dark. 50J.!.I of Stop 
Solution was then added to each well. The absorbance was read at 450nm within 30 minutes of 
stopping reaction. 
MCP-1 ELISA Assay 
MCP-1 production by microglia was determined according to manufacturer's 
recommendations (BD Biosciences-PharMingen, San Diego, CA). For analysis ofMCP-1, 
microwells were coated with lOOJ.!.I per well of Capture Antibody diluted in Coating Buffer. The 
plate was sealed and incubated overnight at 4° C. The wells were aspirated and washed 3 times 
with 300j.l.llwell ofwash buffer. The plates were then blocked with 200J.!.IIwell of Assay Diluent. 
The plate was then incubated at room temperature for I hour. The wells were again aspirated and 
washed 3 times with 300J.!.IIwell ofwash buffer. Standard and sample dilutions in Assay Diluent 
were prepared.) OOJ.!.I of each standard, sample, and control were pipetted into appropriate wells. 
The plate was sealed and incubated for 2 hours at room temperature. The wells were again 
aspirated and washed but with a total of 5 washes. I OOJ.!.I of Working Detector were added to 
each well, and the plate was sealed and incubated for 1 hour at room temperature. The wells 
were then washed again but with 7 total washes. I OOJ.!.I of Substrate Solution were then added to 
each well. Following this step, the plate was left to incubate unsealed in the dark for 30 minutes 
at room temperature. 50J.!.I of Stop Solution were then added to each well. Finally, the absorbance 
was read at 450nm within 30 minutes of stopping the reaction. 
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Results 
The Effect of Mitoxantrone on the viability of N9 microglial cells induced by LPS 
Cell viability was measured with an MTT (3-(4,5-dimethylthiazone-2yl)-2,5-
diphenyltetrazolium bromide) assay, which measures mitochondrial activity. Cells were pre-
treated for 4 hours with the indicated concentrations of the chemotherapy agent mitoxantrone. 
LPS was added as indicated and 24h later cell viability was determined. If the cells were living, 
mitochondria would convert the chemical and show purple color. If cells were dead, there would 
be no purple color. Our results indicated that mitoxantrone does not affect the viability of N9 
microglial cells induced by LPS (Figure 3). 
The Effects of Mitoxantrone on Nitrite Production in N9 Microglia 
Nitrite (NO), in large enough amounts, can be toxic to myelin producing 
oligodendrocytes. This assay was carried out to specifically determine the effect of mitoxantrone 
on NO production in N9 microglia cells. Cells were pre-treated for 4 hours with the indicated 
concentrations ofthe chemotherapy agent mitoxantrone. LPS was added as indicated, and 24h 
later the concentration of nitrite in the culture medium was determined. Our results indicate that 
mitoxantrone significantly inhibits LPS-induced production of nitrite in N9 microglial cells, as 
hypothesized (Figure 4). An MTT assay was performed to determine cell viability, and it was 
revealed that mitoxantrone does not affect N9 microglial viability. From these results, we can 
thus conclude that the LPS-induced inhibition ofNO production by mitoxantrone is not a result 
of the compound's effects on viability. 
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The Effects of Mitoxantrone on IL-6 Production in N9 Microglia 
IL-6 is a cytokine produced by macrophages and has long-range effects that aid in host 
defense. IL-6 is an endogenous pyrogen, meaning it arises from an endogenous source and 
causes fever, which contributes to fighting infection. T cells and B cells augment antigen 
processing and thus increase the adaptive immune response (Janeway and Travers, 1994). In the 
event of an autoimmune disease, T cells attack self tissue "thinking" it is foreign. 
Cells were pre-treated for 4 hours with the indicated concentrations ofthe chemotherapy 
agent mitoxantrone. LPS was added at a final concentration of .0626mg/ml as indicated and 24h 
later the concentration ofiL-6 in the culture medium was determined. It was shown that 
mitoxantrone inhibited the LPS-induced production ofiL-6 in N9 microglial cells. Cell viability 
was determined using an MTT assay, and it was shown that mitoxantrone does not reduce 
microglial cell viability when compared to LPS-treated cells. (See figure 5) 
The Effects of Mitoxantrone on IL-lP Production in N9 Microglia 
Although the procedure to determine IL-l~ (interleukin-1 ~) production by microglia was 
carried out according to the manufacturer's recommendations (BD Biosciences-PharMingen, San 
Diego, CA), the concentration ofLPS was not sufficient to elicit LPS stimulation in the 
microglia cells. The concentration was adjusted in step-wise fashion, but even at a four-fold 
increase in LPS it was still not adequate to stimulate cytokine production. 
The Effects of Mitoxantrone on MCP-1 production in N9 Microglia 
Although the procedure to determine MCP-1 (mouse monocyte chemotactic protein- I) 
production by microglia was carried out according to the manufacturer's recommendations (BD 
Biosciences-PharMingen, San Diego, CA), the resulting data were outside the linear range ofthe 
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plate reader. Therefore, the medium was diluted to 1: 250, but results still remained outside 
linear range. 
LPS Treatment 
.None 
• . 0626J!g/ml 
• . 2504Jlg/ml 
Figure 3. Mitoxantrone does not affect the viability of N9 microglial cells induced by LPS. 
Cells were pre-treated for 4 hours with the indicated concentrations of the chemotherapy agent 
mitoxantrone. LPS was added as indicated and 24h later cell viability was determined. Values 
represent the average for triplicate cultures and standard deviations are indicated. 
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Figure 4. Mitoxantrone inhibits LPS induction of nitrite in N9 microglia cells. 
Cells were pre-treated for 4 hours with the indicated concentrations ofthe chemotherapy agent 
mitoxantrone. LPS was added as indicated and 24h later the concentration of nitrite in the 
culture medium was determined. 
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Figure 5. Mitoxantrone in bib its LPS induction of IL-6 in N9 microglia cells. 
Cells were pre-treated for 4 hours with the indicated concentrations of the chemotherapy agent 
mitoxantrone. LPS was added at a final concentration of .0626mg/ml as indicated and 24h later 
the concentration ofiL-6 in the culture medium was determined. Values represent the average 
for triplicate cultures and standard deviations are indicated. 
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Discussion 
In October of2000, the FDA approved mitoxantrone for treatment of severe forms of 
relapsing-remitting MS and secondary progressive MS (Koeller and Eble, 1988; Jain, 2000). 
However, mitoxantrone has been used to treat various non-lymphocyte leukemias as well as 
prostate and breast cancer since the 1970s, (Neuhaus et al., 2006). MS is thought to be an 
autoimmune disease, and for this reason, immunosuppressants such as mitoxantrone might slow 
the progression of demyelination. Mitoxantrone is a powerful immunosuppressive drug that 
targets proliferating immune cells such as T and B lymphocytes and macrophages (Neuhaus et 
al., 2006). 
Mitoxantrone has been shown to repress microglial activation as well as impede 
proliferation of lymphocytes induced by antigen. The pathway by which mitoxantrone might 
repress activation of microglia in autoimmune disease is mediated by a type of feedback loop 
between cytokines and T-helper cells (Drew, 2005). Activated microglia/macrophages present 
antigen via MHC molecules to CD4+T-helper cells. Subsequently, said T-cells become activated 
which then produce and release cytokines which in tum exacerbates the activation of the 
microglia/macrophages. These molecules, such as NO, TNF-a, and interleukins, released from 
activated microglia, can have an adverse effect on oligodendrocytes. Damaged oligodendrocytes 
result in demyelination of nerves which lead to the severe symptoms MS (Benveniste, 1997). 
Our results indicate that mitoxantrone significantly inhibits LPS-induced production of 
nitrite in N9 microglial cells, as hypothesized. An MTT assay was performed to determine cell 
viability, and it was revealed that mitoxantrone does not affect N9 microglial viability. From 
these results, we can conclude that the LPS-induced inhibition ofNO production by 
mitoxantrone is not a result of the compound's effects on viability. By reducing NO with 
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mitoxantrone, neurodegeneration could be significantly curtailed, implying an alleviation ofMS 
symptoms and heightened viability of myelin-producing oligodendrocytes. Moreover, 
mitoxantrone has also been shown through our studies to inhibit interleukin-6 (IL-6), an 
inflammatory cytokine in microglial cells. As evidenced in Figure 4, IL-6 was inhibited in 
microglial cells by mitoxantrone. The implication is that cytotoxicity of o ligodendrocytes is 
decreased and thus neurodegeneration moderated. 
Although the procedure to determine IL-l p production by microglia was carried out 
according to the manufacturer' s recommendations (BD Biosciences-PharMingen, San Diego, 
CA), the concentration ofLPS was not sufficient to elicit LPS stimulation in the microglia cells. 
The concentration was adjusted in step-wise fashion, even at a four-fold increase in LPS, but it 
was still not adequate to stimulate cytokine production. In the future this assay will continue to 
be run at varied concentrations ofLPS in effort to determine the concentration at which LPS 
stimulation occurs. Similarly, although the procedure to determine MCP-1 (mouse monocyte 
chemotactic protein- I) production by microglia was carried out according to the manufacturer's 
recommendations (BD Biosciences-PharMingen, San Diego, CA), the resulting data were 
outside the linear range of the plate reader. Therefore, the medium was diluted to 
1: 250, but results still remained outside linear range. This assay will continue to be run at varied 
dilutions of media samples until samples fall into the linear range. 
In conclusion, mitoxantrone was seen to maintain an inhibitory effect on LPS-induced N9 
microglial cell activation. Specifically, these effects include the marked decrease of 
proinflammatory molecules such as NO and IL-6. As it has been observed that these molecules 
mediate pathogenesis of the neurodegenerative disease multiple sclerosis, the repression of 
activated microglia could potentially lead to an increase in oligodendrocyte viability and, thus, 
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lessened severity of multiple sclerosis. Our lab plans to investigate a new agent, ajulemic acid, 
using the same experiments described here. Our hope is that it will modulate microglial 
activation in a similar manner and may one day provide a safe and more effective treatment 
option for those living with MS. 
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